Inspira Technologies has signed an exclusive summary distribution agreement with Glo-Med Networks.

According to the terms of the agreement, Glo-Med Networks will distribute Inspira’s HYLA blood sensor device, as well as disposable units, in the US states of New Jersey, South Carolina, North Carlina, Florida, Texas and New York.

The HYLA non-invasive blood sensor provides quick, real-time and continuous vital blood monitoring without using actual blood samples from patients.

The device is designed to continuously measure many important indicators, including partial oxygen levels and carbon dioxide pressures, which are said to be accurate indicators of a patient’s health disorders and deterioration.

Inspira Technologies stated that real-time patient blood monitoring provides alerts for physicians that allow them to potentially save more lives.

The HYLA blood sensor is claimed to benefit patients undergoing intensive care unit (ICU) monitoring, extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, dialysis and cardiopulmonary bypass.

The distribution agreement, which is subject to the completion of product development and regulatory approvals, has an initial term of three years and will be followed by a more comprehensive deal.

Glo-Med has committed to purchasing 3,889 HYLA blood sensors and 264,873 disposable units for deployment at hospitals and medical centres.

Glo-Med CEO Matus Knoblich said: “I believe that this ground-breaking technology may dramatically reduce the need for actual blood sampling by the hospital staff.

“This could significantly reduce their workload while providing potentially critical information at a critical moment when a patient’s medical condition may suddenly deteriorate without warning.

“I strongly believe that this technology has the potential to eventually become a device for almost every patient in ICUs and other suitable clinical settings.”

The latest deal is Inspira’s second distribution agreement with Glo-Med. The first deal, for the distribution of the company’s ART system in the US, was signed in January.

Inspira noted that the HYLA blood sensor and ART system have not been tested or used in humans.